| Budget Amount *help |
¥9,490,000 (Direct Cost: ¥7,300,000、Indirect Cost: ¥2,190,000)
Fiscal Year 2016: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
Fiscal Year 2015: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
Fiscal Year 2014: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
|
|---|
| Outline of Final Research Achievements |
Adult T-cell leukemia/lymphoma (ATL) is a hematological malignancy caused by HTLV-I infection. ATL is refractory to chemotherapy and the prognosis of patients with ATL is extremely poor. We have revealed that cytotoxic T-cells (CTLs) against Tax, a protein produced by HTLV-I, increased after allogeneic hematopoietic stem cell transplantation for ATL and found that CTLs with T-cell receptor (TCR) repertoir containing "PDR" motif exhibit strong cytotoxic activity against HTLV-I infected cells. In addition, we produced redirected Tax-specific CTL by transducing the full-length TCR alpha and beta genes of the "PDR"-containing TCR to peripheral blood mononuclear cells from healthy volunteers using retroviral vector, and showed that the redirected CTLs also had strong cytotoxic activity against HTLV-I infected cells both in vitro and in vivo (patent pending).
|
